Adoptive immunotherapy of advanced tumors with CD62 L-selectinlow tumor-sensitized T lymphocytes following ex vivo hyperexpansion

Journal of Immunology

Volumn 169, Issue 6, 2002, Pages 3314-3320

  Wang, Li Xin ^a   Chen, Bing Guan ^a   Plautz, Gregory E ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; L SELECTIN; PADGEM PROTEIN;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CELL ACTIVATION; CELL COUNT; CELL CULTURE; CELL POPULATION; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HELPER CELL; IMMUNOLOGICAL MEMORY; IMMUNOPHARMACOLOGY; LUNG METASTASIS; LYMPH NODE CELL; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0037105416     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.169.6.3314     Document Type: Article

References (50)

1. T-cell adoptive therapy of tumors: Mechanisms of improved therapeutic performance
2. Progress in human tumour immunology and immunotherapy
3. Immune responses to turnout antigens: Implications for antigen specific immunotherapy of cancer
4. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas
5. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma
6. Cytolytic T lymphocyte clones from peripheral blood and from tumor site detect intratumor heterogeneity of melanoma cells
7. Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A*0201-restricted E7-encoded epitope
8. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
9. + T cell responses using MHC/peptide tetramers in cancer patients
10. Ex vivo IFN-γ secretion by circulating CD8 T lymphocytes: Implications of a novel approach for T cell monitoring in infectious and malignant diseases
11. Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer
12. Naturally occurring prostate cancer antigen-specific T cell responses of a Th1 phenotype can be detected in patients with prostate cancer
13. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression
14. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients
15. Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical caminoma
16. + T cells after vaccination with antigenic peptide
17. + T lymphocytes in peripheral blood of patients with advanced melanoma
18. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
19. Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy
20. Tumor-induced interleukin-10 inhibits type I immune responses directed at a tumor antigen as well as a non-tumor antigen present at the tumor site
21. Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells
22. Effects of TGF-β on the immune system: Implications for cancer immunotherapy
23. Ex vivo activation of tumor-draining lymph node T cells reverses defects in signal transduction molecules
24. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2
25. Isolation based on L-selectin expression of immune effector T cells derived from tumor-draining lymph nodes
26. low cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes
27. Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells
28. + T cells with broad anti-tumor efficacy are naturally sensitized during tumor progression
29. Antigen-specific development of primary and memory T cells in vivo
30. Naive and effector CD4 T cells differ in their requirements for T cell receptor versus costimulatory signals
31. + T cell response
32. + T cells
33. Ex vivo staining of metastatic lymph nodes by class 1 major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolyfic T lymphocytes
34. Adoptive tumor therapy with T lymphocytes enriched through an IFN-γ capture assay
35. + T cells from melanoma patients reveals inefficient antigen processing
36. An antigen-targeted approach to adoptive transfer therapy of cancer
37. In vivo antitumor activity of anti-CD3-induced activated killer cells
38. + IL-2-stimulated murine killer cells: In vitro generation and in vivo antitumor activity
39. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes
40. Synergistic antitumor activity of tumor-infiltrating lymphocytes, interleukin 2, and local tumor irradiation
41. Unique characteristics associated with systemic adoptive immunotherapy of experimental intra-cerebral tumors
42. Augmentation versus inhibition: Effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor
43. + T cells: Efficacy is limited by migration away from the site and induction of nonresponsiveness
44. Signaling alterations in activation-induced nonresponsive CD8 T cells
45. Two distinct stages in the transition from naive CD4 T cells to effectors, early antigen-dependent and late cytokine-driven expansion and differentiation
46. Qualitative changes accompany memory T cell generation: Faster, more effective responses at lower doses of antigen
47. Can the low-avidity self-specific T cell repertoire be exploited for tumor rejection?
48. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction
49. Immune surveillance against a solid tumor fails because of immunological ignorance
50. Infiltration of tumors by systemically transferred tumor-reactive T lymphocytes is required for antitumor efficacy